# COL3A1

## Overview
The COL3A1 gene encodes the collagen type III alpha 1 chain, a critical component of type III collagen, which is a fibrillar collagen protein. This protein plays a vital role in the structural integrity and function of various connective tissues, including skin, blood vessels, and internal organs. Type III collagen is characterized by its triple-helical structure, which provides tensile strength and elasticity to tissues that require flexibility, such as large blood vessels, the uterus, and the bowel (Kuivaniemi2019Type). The gene's expression and the protein's interactions with other collagen types and integrins are essential for maintaining the extracellular matrix's architecture and function. Mutations in COL3A1 are associated with vascular Ehlers-Danlos syndrome and other connective tissue disorders, highlighting its clinical significance (Ruscitti2021A; Frank2015The).

## Structure
The COL3A1 gene encodes the collagen alpha-1(III) chain, a protein that forms type III collagen, a major structural component in hollow organs such as large blood vessels, uterus, and bowel (Kuivaniemi2019Type). The primary structure of type III collagen consists of a sequence of approximately 1,000 amino acids, with glycine as every third residue, forming a (Gly-Xaa-Yaa)n repeat. Proline or hydroxyproline often occupies the X and Y positions, contributing to the stability of the triple helix (Kuivaniemi2019Type). 

The secondary structure involves each chain folding into a left-handed helix, which then wraps into a right-handed superhelix, forming the triple helix (Kuivaniemi2019Type). The tertiary structure is stabilized by disulfide bonds at the C-terminal ends of the three identical procollagen chains (Kuivaniemi2019Type). The quaternary structure involves the assembly of type III collagen monomers into macromolecular fibrils in the extracellular space, which aggregate into fibers (Kuivaniemi2019Type).

Post-translational modifications include hydroxylation of proline residues to 4-hydroxyproline, glycosylation, and oxidative deamination of lysine residues (Kuivaniemi2019Type). The C-propeptide, crucial for biosynthesis, contains eight cysteine residues and an N-glycosylation site, facilitating chain selection and triple helix formation (Kuivaniemi2019Type).

## Function
The COL3A1 gene encodes the collagen alpha-1(III) chain, a crucial component of type III collagen, which is a major structural protein in the extracellular matrix of various tissues, including skin, blood vessels, and internal organs. In healthy human cells, type III collagen is synthesized as a pre-procollagen, which undergoes post-translational modifications to form a stable triple-helical structure. This structure is essential for providing tensile strength and elasticity to tissues that require flexibility and resilience, such as large blood vessels, the uterus, and the bowel (Kuivaniemi2019Type).

Type III collagen interacts with type I and II collagens to regulate fibril diameter and contribute to the formation of thinner fibrils, which are important for maintaining the structural integrity of tissues (Kuivaniemi2019Type). It also plays a significant role in platelet aggregation and the initiation of the blood clotting cascade, highlighting its importance in wound healing and hemostasis (Kuivaniemi2019Type). Additionally, type III collagen is involved in cell adhesion, migration, proliferation, and differentiation through interactions with integrins, which are critical for maintaining tissue architecture and function (Kuivaniemi2019Type).

## Clinical Significance
Mutations in the COL3A1 gene are primarily associated with vascular Ehlers-Danlos syndrome (vEDS), a severe form of Ehlers-Danlos syndrome characterized by life-threatening complications such as arterial ruptures, bowel perforations, and uterine ruptures (Ruscitti2021A; Frank2015The). These mutations often result in abnormal type III collagen, which compromises the structural integrity of connective tissues (Cortini2016Nextgeneration). The clinical presentation of vEDS can include thin, translucent skin, easy bruising, and joint hypermobility, particularly in the fingers (Kuivaniemi1997Mutations).

The severity of vEDS is influenced by the type of COL3A1 mutation. Glycine substitutions and splice-site mutations are among the most severe, while haploinsufficiency mutations tend to result in a milder phenotype with delayed onset of complications (Leistritz2011COL3A1haploinsufficiency; Frank2015The). Mosaicism has been observed in some cases, contributing to variability in clinical manifestations (Kuivaniemi2019Type).

In addition to vEDS, COL3A1 mutations have been linked to other conditions, such as brain abnormalities and fibrotic diseases, due to altered collagen expression and interactions (Kuivaniemi2019Type). These mutations can lead to increased collagen deposition, affecting tissue function and integrity.

## Interactions
The COL3A1 gene encodes type III collagen, which is involved in various physical interactions crucial for its biological functions. Type III collagen interacts with platelets through specific glycoproteins and non-integrin receptors, facilitating platelet adhesion. This interaction is mediated by a 47-kDa membrane protein isolated from platelets that binds to type III collagen (Kuivaniemi2019Type). It also interacts with integrins, which are cell surface receptors that play roles in cell adhesion, migration, proliferation, and differentiation. The high-affinity binding sites for integrins are located in the C-terminal region of type III procollagen (Kuivaniemi2019Type).

In the context of the extracellular matrix (ECM), type III collagen interacts with fibronectin and other collagen types, such as type I and V, forming heterotypic fibrils essential for ECM assembly and tissue integrity. Mutations in COL3A1 can disrupt these interactions, leading to altered cell adhesion and migration (Zoppi2004Human). Additionally, type III collagen's interaction with other proteins is implicated in wound healing, as evidenced by increased levels of its N-terminal propeptide in surgical patients, indicating its role in tissue repair processes (Kuivaniemi2019Type).


## References


[1. (Kuivaniemi1997Mutations) Helena Kuivaniemi, Gerard Tromp, and Darwin J. Prockop. Mutations in fibrillar collagens (types i, ii, iii, and xi), fibril-associated collagen (type ix), and network-forming collagen (type x) cause a spectrum of diseases of bone, cartilage, and blood vessels. Human Mutation, 9(4):300–315, 1997. URL: http://dx.doi.org/10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9, doi:10.1002/(sici)1098-1004(1997)9:4<300::aid-humu2>3.0.co;2-9. This article has 465 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/(SICI)1098-1004(1997)9:4)

[2. (Kuivaniemi2019Type) Helena Kuivaniemi and Gerard Tromp. Type iii collagen (col3a1): gene and protein structure, tissue distribution, and associated diseases. Gene, 707:151–171, July 2019. URL: http://dx.doi.org/10.1016/j.gene.2019.05.003, doi:10.1016/j.gene.2019.05.003. This article has 210 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2019.05.003)

[3. (Zoppi2004Human) Nicoletta Zoppi, Rita Gardella, Anne De Paepe, Sergio Barlati, and Marina Colombi. Human fibroblasts with mutations in col5a1 and col3a1 genes do not organize collagens and fibronectin in the extracellular matrix, down-regulate α2β1 integrin, and recruit αvβ3 instead of α5β1 integrin. Journal of Biological Chemistry, 279(18):18157–18168, April 2004. URL: http://dx.doi.org/10.1074/JBC.M312609200, doi:10.1074/jbc.m312609200. This article has 126 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M312609200)

[4. (Frank2015The) Michael Frank, Juliette Albuisson, Brigitte Ranque, Lisa Golmard, Jean-Michael Mazzella, Laurence Bal-Theoleyre, Anne-Laure Fauret, Tristan Mirault, Nicolas Denarié, Elie Mousseaux, Pierre Boutouyrie, Jean-Noël Fiessinger, Joseph Emmerich, Emmanuel Messas, and Xavier Jeunemaitre. The type of variants at the col3a1 gene associates with the phenotype and severity of vascular ehlers–danlos syndrome. European Journal of Human Genetics, 23(12):1657–1664, March 2015. URL: http://dx.doi.org/10.1038/ejhg.2015.32, doi:10.1038/ejhg.2015.32. This article has 163 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2015.32)

[5. (Leistritz2011COL3A1haploinsufficiency) Dru F. Leistritz, Melanie G. Pepin, Ulrike Schwarze, and Peter H. Byers. Col3a1haploinsufficiency results in a variety of ehlers-danlos syndrome type iv with delayed onset of complications and longer life expectancy. Genetics in Medicine, 13(8):717–722, August 2011. URL: http://dx.doi.org/10.1097/gim.0b013e3182180c89, doi:10.1097/gim.0b013e3182180c89. This article has 90 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1097/gim.0b013e3182180c89)

[6. (Ruscitti2021A) Federica Ruscitti, Lucia Trevisan, Giulia Rosti, Fabio Gotta, Annalia Cianflone, Alessandro Geroldi, Paola Origone, Anna Pichiecchio, Simona Viglio, Maria Iascone, and Paola Mandich. A novel mutation in col3a1 associates to vascular ehlers–danlos syndrome with predominant musculoskeletal involvement. Molecular Genetics &amp; Genomic Medicine, July 2021. URL: http://dx.doi.org/10.1002/mgg3.1753, doi:10.1002/mgg3.1753. This article has 3 citations.](https://doi.org/10.1002/mgg3.1753)

[7. (Cortini2016Nextgeneration) Francesca Cortini, Barbara Marinelli, Manuela Seia, Barbara De Giorgio, Angela Cecilia Pesatori, Nicola Montano, and Alessandra Bassotti. Next-generation sequencing and a novel col3a1 mutation associated with vascular ehlers–danlos syndrome with severe intestinal involvement: a case report. Journal of Medical Case Reports, October 2016. URL: http://dx.doi.org/10.1186/s13256-016-1087-0, doi:10.1186/s13256-016-1087-0. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13256-016-1087-0)